Pub Date : 2022-04-01DOI: 10.1016/j.ghir.2022.101459
Yogesh C. Bangar, Ankit Magotra, A.S. Yadav, C.S. Patil
Objective
The present work aimed to obtain common effect sizes for the gene frequency and association of MspI derived variants of growth hormone (GH) gene with milk yield in dairy cows.
Methods
We performed a systematic review and meta-analysis of 35 published studies identified in literature search from 2000 to 2020 (n = 4164). These studies were specific to fragment size (329) for genotypes viz., CC (224, 105 bp), CD (329, 224, 105 bp) and DD (329 bp). Pooled standard mean differences (SMDs) as effect sizes between allele pairs were derived using different genetic models. The heterogeneity between effects sizes across studies was estimated using I2 Index (%).
Results
The common effect size for gene frequency of allele C (224, 105 bp) was significantly (P < 0.05) higher in 2881 Bos taurus/cross cows (0.82; 95% CI: 0.74, 0.89; I2 = 97.81%) than 1283 Bos indicus cows (0.15; 95% CI: 0.12, 0.18; I2 = 71.90%), with overall gene frequency was 0.33 (95% CI: 0.21, 0.46; I2 = 99.29%). Additive (CC vs. DD) and dominant (CC + CD vs. DD) did not revealed significant (P > 0.05) association with milk yield. However, completely over dominant (CC + DD vs. CD) and recessive (CC vs. CD + DD) models showed significant (P < 0.05) and positive SMDs with milk yield specially at early lactations. There was no evidence of heterogeneity (I2 = 0.00%) between SMDs across studies.
Conclusions
This meta-analysis suggested potential association of C allele for enhancing milk production of dairy cows.
目的研究奶牛生长激素(GH)基因MspI衍生变异的基因频率及其与产奶量的关系。方法:我们对2000年至2020年文献检索中已发表的35项研究(n = 4164)进行了系统回顾和荟萃分析。这些研究是针对基因型的片段大小(329)进行的,即CC (224, 105 bp), CD (329, 224, 105 bp)和DD (329 bp)。利用不同的遗传模型推导出等位基因对间的效应大小。使用I2指数(%)估计各研究间效应大小的异质性。结果等位基因C基因频率的共同效应量(224,105 bp)显著(P <2881头牛/杂交牛(0.82;95% ci: 0.74, 0.89;I2 = 97.81%)高于1283头母牛(0.15;95% ci: 0.12, 0.18;I2 = 71.90%),总基因频率为0.33 (95% CI: 0.21, 0.46;i2 = 99.29%)。加性(CC vs. DD)和显性(CC + CD vs. DD)无显著差异(P >0.05)与产奶量相关。然而,完全过显性(CC + DD vs. CD)和隐性(CC vs. CD + DD)模型显示显著(P <0.05), smd阳性与泌乳量有关,尤其是在泌乳早期。没有证据表明不同研究的smd之间存在异质性(I2 = 0.00%)。结论本荟萃分析提示C等位基因与奶牛产奶量的潜在关联。
{"title":"Meta-analysis of MspI derived variants of growth hormone gene associated with milk yield in dairy cattle","authors":"Yogesh C. Bangar, Ankit Magotra, A.S. Yadav, C.S. Patil","doi":"10.1016/j.ghir.2022.101459","DOIUrl":"10.1016/j.ghir.2022.101459","url":null,"abstract":"<div><h3>Objective</h3><p>The present work aimed to obtain common effect sizes for the gene frequency and association of <em>Msp</em>I derived variants of growth hormone (GH) gene with milk yield in dairy cows.</p></div><div><h3>Methods</h3><p><span>We performed a systematic review and meta-analysis of 35 published studies identified in literature search from 2000 to 2020 (</span><em>n</em> = 4164). These studies were specific to fragment size (329) for genotypes viz.<em>,</em> CC (224, 105 bp), CD (329, 224, 105 bp) and DD (329 bp). Pooled standard mean differences (SMDs) as effect sizes between allele pairs were derived using different genetic models. The heterogeneity between effects sizes across studies was estimated using I<sup>2</sup> Index (%).</p></div><div><h3>Results</h3><p>The common effect size for gene frequency of allele C (224, 105 bp) was significantly (<em>P</em> < 0.05) higher in 2881 <span><em>Bos taurus</em></span>/cross cows (0.82; 95% CI: 0.74, 0.89; I<sup>2</sup> = 97.81%) than 1283 <span><em>Bos indicus</em></span> cows (0.15; 95% CI: 0.12, 0.18; I<sup>2</sup> = 71.90%), with overall gene frequency was 0.33 (95% CI: 0.21, 0.46; I<sup>2</sup> = 99.29%). Additive (CC vs. DD) and dominant (CC + CD vs. DD) did not revealed significant (<em>P</em> > 0.05) association with milk yield. However, completely over dominant (CC + DD vs. CD) and recessive (CC vs. CD + DD) models showed significant (<em>P</em><span> < 0.05) and positive SMDs with milk yield specially at early lactations. There was no evidence of heterogeneity (I</span><sup>2</sup> = 0.00%) between SMDs across studies.</p></div><div><h3>Conclusions</h3><p>This meta-analysis suggested potential association of C allele for enhancing milk production of dairy cows.</p></div>","PeriodicalId":12803,"journal":{"name":"Growth Hormone & Igf Research","volume":"63 ","pages":"Article 101459"},"PeriodicalIF":1.4,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84620827","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-04-01DOI: 10.1016/j.ghir.2022.101458
Julie Chen , Laurence Katznelson
Growth hormone (GH) is an important regulator of the female reproductive system. In vitro and non-human in vivo studies demonstrate a role of GH in steroidogenesis, folliculogenesis, and post-fertilization development. Given its ability to modulate the reproductive system and potentiate the effects of gonadotropins, a beneficial role of GH replacement therapy to optimize fertility has been suggested. Women with hypopituitarism have lower pregnancy and live birth rates. Limited data suggest a role of GH in enhancing fertility management in women with hypopituitarism. GH replacement therapy may be especially relevant in women with hypopituitarism as well as in women considered poor ovarian responders and require assisted reproductive techniques.
{"title":"The role of growth hormone for fertility in women with hypopituitarism","authors":"Julie Chen , Laurence Katznelson","doi":"10.1016/j.ghir.2022.101458","DOIUrl":"10.1016/j.ghir.2022.101458","url":null,"abstract":"<div><p><span><span>Growth hormone (GH) is an important regulator of the female reproductive system. In vitro and non-human in vivo studies demonstrate a role of GH in </span>steroidogenesis, </span>folliculogenesis<span><span>, and post-fertilization development. Given its ability to modulate the reproductive system and potentiate the effects of gonadotropins<span>, a beneficial role of GH replacement therapy to optimize fertility has been suggested. Women with hypopituitarism have lower pregnancy and live birth rates. Limited data suggest a role of GH in enhancing fertility management in women with hypopituitarism. GH replacement therapy may be especially relevant in women with hypopituitarism as well as in women considered poor ovarian responders and require </span></span>assisted reproductive techniques.</span></p></div>","PeriodicalId":12803,"journal":{"name":"Growth Hormone & Igf Research","volume":"63 ","pages":"Article 101458"},"PeriodicalIF":1.4,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78765154","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-04-01DOI: 10.1016/j.ghir.2022.101456
Jithine Jayakumar Rajeswari , Emilio J. Vélez , Suraj Unniappan
Objective
Phoenixin-20 (Pnx-20) is a bioactive peptide with endocrine-like actions in vertebrates. Recent studies suggest Pnx-20 promotes growth hormone/insulin-like growth factors (Gh/Igf) axis, an important endocrine regulator of growth in mammals and fish.
Design
In this research, we determined whether Pnx-20 affects the different members of the Igf family, its binding proteins and receptors (Igf-system) in zebrafish liver and muscle.
Results
In vivo administration of Pnx-20 downregulated igfs, igf receptors (igfrs) and igf binding protein (igfbp) 5 mRNA expression in the liver of male and female zebrafish at both 1 and 6 h post-intraperitoneal (IP) injection. Interestingly, this effect occurred at a relatively earlier timepoint in female zebrafish suggesting sex-specific differences in Pnx-20 action. Besides, either 6 or 24 h in vitro incubations with Pnx-20 downregulated the expression of all igfs, igfrs and igfbp5 mRNAs (except igf2a) analyzed in a zebrafish liver cell (ZFL) line. Moreover, siRNA-mediated knockdown of Pnx-20 upregulated all Igf-system mRNAs analyzed in ZFL cells. Together, these results (both in vivo and in vitro) revealed a general suppressive action for both endogenous and exogenous Pnx-20 on the hepatic Igf-system of zebrafish. In contrast, a general sex-specific upregulation of the Igf-system mRNAs analyzed was found in the muscle of Pnx-20 injected fish. Future research should explore the sex- and time-differences observed in the present study.
Conclusions
Collectively, this research shows that Pnx-20 is a tissue-specific regulator of the liver (suppressor) and muscle (stimulant) Igf signaling in both male and female zebrafish.
{"title":"Liver and muscle-specific effects of phoenixin-20 on the insulin-like growth factor system mRNAs in zebrafish","authors":"Jithine Jayakumar Rajeswari , Emilio J. Vélez , Suraj Unniappan","doi":"10.1016/j.ghir.2022.101456","DOIUrl":"10.1016/j.ghir.2022.101456","url":null,"abstract":"<div><h3>Objective</h3><p>Phoenixin-20 (Pnx-20) is a bioactive peptide with endocrine-like actions in vertebrates. Recent studies suggest Pnx-20 promotes growth hormone/insulin-like growth factors (Gh/Igf) axis, an important endocrine regulator of growth in mammals and fish.</p></div><div><h3>Design</h3><p>In this research, we determined whether Pnx-20 affects the different members of the Igf family, its binding proteins and receptors (Igf-system) in zebrafish liver and muscle.</p></div><div><h3>Results</h3><p><em>In vivo</em> administration of Pnx-20 downregulated <em>igfs</em>, <em>igf</em> receptor<em>s</em> (<em>igfrs</em>) and <em>igf</em> binding protein (<em>igfbp</em>) 5 mRNA expression in the liver of male and female zebrafish at both 1 and 6 h post-intraperitoneal (IP) injection. Interestingly, this effect occurred at a relatively earlier timepoint in female zebrafish suggesting sex-specific differences in Pnx-20 action. Besides, either 6 or 24 h <em>in vitro</em> incubations with Pnx-20 downregulated the expression of all <em>igfs</em>, <em>igf</em>rs and <span><em>igfbp5</em></span> mRNAs (except <em>igf2a</em>) analyzed in a zebrafish liver cell (ZFL) line. Moreover, siRNA-mediated knockdown of Pnx-20 upregulated all Igf-system mRNAs analyzed in ZFL cells. Together, these results (both <em>in vivo</em> and <em>in vitro</em>) revealed a general suppressive action for both endogenous and exogenous Pnx-20 on the hepatic Igf-system of zebrafish. In contrast, a general sex-specific upregulation of the Igf-system mRNAs analyzed was found in the muscle of Pnx-20 injected fish. Future research should explore the sex- and time-differences observed in the present study.</p></div><div><h3>Conclusions</h3><p>Collectively, this research shows that Pnx-20 is a tissue-specific regulator of the liver (suppressor) and muscle (stimulant) Igf signaling in both male and female zebrafish.</p></div>","PeriodicalId":12803,"journal":{"name":"Growth Hormone & Igf Research","volume":"63 ","pages":"Article 101456"},"PeriodicalIF":1.4,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77836395","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-04-01DOI: 10.1016/j.ghir.2022.101457
Maria Maddalena Sirufo , Lina Maria Magnanimi , Lia Ginaldi , Massimo De Martinis
This is the story of a giant who lived in Abruzzo 200 years ago. He became a symbol for his people and a strong resilience generator. Gigantism, in the history of humanity has always attracted attention, albeit passing over the centuries from myth, from divinity to the freak phenomenon, the freak of nature that becomes a spectacle to show off. The attraction for understanding the pathophysiological mechanisms underlying gigantism developed by the end of 19th century. Increased levels of growth hormone (GH) or insulin-like growth hormone 1 (IGF1) causes overgrowth in pituitary gigantism. The imposing size of the body, in our imagination, represents strength and health, reason why in our imagination it almost becomes a divine mythical image. The story of the Acciano's Giant represents a cultural heritage that passes from one generation to the next, that contributes in giving a sense of identity and continuity. It provides a link from past to present and to the future. Encourages a sense of identity and responsibility contributing to social cohesion, helping individuals to feel members of one community. A disease, represented by the Giant, has become a symbol capable of bringing the community together and giving it the strength to react to environment, nature and history. This is a lesson that teaches us the sense of community.
{"title":"The true story of the “strong and gentle” Acciano's Giant","authors":"Maria Maddalena Sirufo , Lina Maria Magnanimi , Lia Ginaldi , Massimo De Martinis","doi":"10.1016/j.ghir.2022.101457","DOIUrl":"10.1016/j.ghir.2022.101457","url":null,"abstract":"<div><p><span>This is the story of a giant who lived in Abruzzo 200 years ago. He became a symbol for his people and a strong resilience generator. Gigantism, in the history of humanity has always attracted attention, albeit passing over the centuries from myth, from divinity to the freak phenomenon, the freak of nature that becomes a spectacle to show off. The attraction for understanding the pathophysiological mechanisms underlying gigantism developed by the end of 19th century. Increased levels of growth hormone (GH) or insulin-like </span>growth hormone 1 (IGF1) causes overgrowth in pituitary gigantism. The imposing size of the body, in our imagination, represents strength and health, reason why in our imagination it almost becomes a divine mythical image. The story of the Acciano's Giant represents a cultural heritage that passes from one generation to the next, that contributes in giving a sense of identity and continuity. It provides a link from past to present and to the future. Encourages a sense of identity and responsibility contributing to social cohesion, helping individuals to feel members of one community. A disease, represented by the Giant, has become a symbol capable of bringing the community together and giving it the strength to react to environment, nature and history. This is a lesson that teaches us the sense of community.</p></div>","PeriodicalId":12803,"journal":{"name":"Growth Hormone & Igf Research","volume":"63 ","pages":"Article 101457"},"PeriodicalIF":1.4,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40325446","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-04-01DOI: 10.1016/j.ghir.2022.101445
Michihiro Kon , Yoshiko Ebi , Kohei Nakagaki
Objective
Hyperoxic gas inhalation during exercise may negatively affect all-out sprint interval exercise (SIE)-induced hormonal, metabolic, and angiogenic responses. We investigated the effects of acute all-out SIE under systemic hyperoxia on hormonal, metabolic, and angiogenic responses.
Design
This was a randomised-crossover trial. Ten healthy males (mean ± standard error of age = 23.1 ± 0.9 years; height = 171.0 ± 1.6 cm; body mass = 66.2 ± 2.0 kg; body mass index = 22.6 ± 0.5 kg/m2) completed the following two experimental regimens: 1) SIE under normoxia and 2) SIE under systemic hyperoxia (FiO2 = 60%). The subjects performed four bouts of 30-s maximal cycling efforts with 4 min recovery between efforts. The circulating levels of hormonal (growth hormone, epinephrine, and norepinephrine), metabolic (glucose, free fatty acid, and lactate), and angiogenic (vascular endothelial growth factor, matrix metalloproteinase-2 and -9, and endostatin) markers were measured before and at 0 (immediately after the regimen), 30, and 120 min after both regimens.
Results
In response to both SIE regimens, the peak and mean power outputs gradually decreased over the intermittent exercise session compared with those in the first bout (p < 0.01) with no significant differences between the regimens. Both regimens significantly increased the circulating concentrations of all hormonal, metabolic, and angiogenic markers (p < 0.01). However, there were no significant differences in the levels of these markers in response to the two regimens at any time point (p > 0.05).
Conclusion
These findings suggest that acute systemic hyperoxia does not influence the hormonal, metabolic, and angiogenic responses to all-out SIE.
{"title":"Hormonal, metabolic, and angiogenic responses to all-out sprint interval exercise under systemic hyperoxia","authors":"Michihiro Kon , Yoshiko Ebi , Kohei Nakagaki","doi":"10.1016/j.ghir.2022.101445","DOIUrl":"10.1016/j.ghir.2022.101445","url":null,"abstract":"<div><h3>Objective</h3><p>Hyperoxic gas inhalation during exercise may negatively affect all-out sprint interval exercise (SIE)-induced hormonal, metabolic, and angiogenic responses. We investigated the effects of acute all-out SIE under systemic hyperoxia on hormonal, metabolic, and angiogenic responses.</p></div><div><h3>Design</h3><p><span>This was a randomised-crossover trial. Ten healthy males (mean ± standard error of age = 23.1 ± 0.9 years; height = 171.0 ± 1.6 cm; body mass = 66.2 ± 2.0 kg; body mass index = 22.6 ± 0.5 kg/m</span><sup>2</sup>) completed the following two experimental regimens: 1) SIE under normoxia and 2) SIE under systemic hyperoxia (FiO<sub>2</sub><span> = 60%). The subjects performed four bouts of 30-s maximal cycling efforts with 4 min recovery between efforts. The circulating levels of hormonal (growth hormone, epinephrine, and norepinephrine), metabolic (glucose, free fatty acid, and lactate), and angiogenic (vascular endothelial growth factor, matrix metalloproteinase-2 and -9, and endostatin) markers were measured before and at 0 (immediately after the regimen), 30, and 120 min after both regimens.</span></p></div><div><h3>Results</h3><p>In response to both SIE regimens, the peak and mean power outputs gradually decreased over the intermittent exercise session compared with those in the first bout (p < 0.01) with no significant differences between the regimens. Both regimens significantly increased the circulating concentrations of all hormonal, metabolic, and angiogenic markers (p < 0.01). However, there were no significant differences in the levels of these markers in response to the two regimens at any time point (p > 0.05).</p></div><div><h3>Conclusion</h3><p>These findings suggest that acute systemic hyperoxia does not influence the hormonal, metabolic, and angiogenic responses to all-out SIE.</p></div>","PeriodicalId":12803,"journal":{"name":"Growth Hormone & Igf Research","volume":"63 ","pages":"Article 101445"},"PeriodicalIF":1.4,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39926431","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-02-01DOI: 10.1016/j.ghir.2022.101446
Qin Shen , Xia Wang , Haodi Bai , Xin Tan , Xing Liu
Objective
The signaling axis consisting of GH-IGF1-IGFBP3 is the primary signal taht acts prepubertally to influence height development. Growth plate thinning and even premature closure have been reported in children with tumors treated with retinoid chemotherapy, resulting in long bone dysplasia. Growth failure may occur despite received GH treatment, but the reason is unknown. This study investigate the effect of high-dose all-trans retinoic acid (ATRA) on the development of long bones in growing SD rats.
Methods
A total of 20 three-week-old male SD rats were randomly divided into a control group and an experimental group (n = 10). Rats were treated by gavage with or without high-dose ATRA for 10 days. The body weights of the rats were recorded daily. At the end of the experiment, we measured the length of nose-tail and tibia, stained the tibia and liver for pathological tissue and RT-PCR reaction, and measured the levels of serum GH, IGF1 and IGFBP3, and so on.
Results
Compared with controls, experimental rats exhibited reduced body weight and shortened nasal-tail and radial tibial length. Cyp26b1 enzyme activity in the liver was elevated, and histopathological staining revealed that the cartilaginous epiphyseal plate was narrowed, the medullary cavity of trabecular bone was sparse, the number of trabecular bones was decreased, trabecular separation was increased, bone marrow mineralization was enhanced, osteoclastic activity was increased, and circulating GH-IGF1-IGFBP3 levels were decreased. However, RT-PCR reaction results of localized proximal tibiae showed upregulation of IGF1 and downregulation of IGFBP3.
Conclusions
High-dose ATRA intake over a short period of time can reduce GH-IGF1-IGFBP3 levels, affect cartilage and bone homeostasis, and inhibit bone growth in developing animals.
{"title":"Effects of high-dose all-trans retinoic acid on longitudinal bone growth of young rats","authors":"Qin Shen , Xia Wang , Haodi Bai , Xin Tan , Xing Liu","doi":"10.1016/j.ghir.2022.101446","DOIUrl":"10.1016/j.ghir.2022.101446","url":null,"abstract":"<div><h3>Objective</h3><p>The signaling axis consisting of GH-IGF1-IGFBP3 is the primary signal taht acts prepubertally to influence height development. Growth plate<span><span><span><span> thinning and even premature closure have been reported in children with tumors treated with retinoid chemotherapy, resulting in long </span>bone dysplasia. Growth failure may occur despite received GH </span>treatment<span>, but the reason is unknown. This study investigate the effect of high-dose all-trans retinoic acid (ATRA) on the development of long bones in growing </span></span>SD rats.</span></p></div><div><h3>Methods</h3><p>A total of 20 three-week-old male SD rats were randomly divided into a control group and an experimental group (<em>n</em><span> = 10). Rats were treated by gavage with or without high-dose ATRA for 10 days. The body weights of the rats were recorded daily. At the end of the experiment, we measured the length of nose-tail and tibia<span>, stained the tibia and liver for pathological tissue<span><span> and RT-PCR reaction, and measured the levels of serum GH, IGF1 and </span>IGFBP3, and so on.</span></span></span></p></div><div><h3>Results</h3><p>Compared with controls, experimental rats exhibited reduced body weight and shortened nasal-tail and radial tibial length. Cyp26b1 enzyme activity<span><span><span> in the liver was elevated, and histopathological staining revealed that the cartilaginous epiphyseal plate was narrowed, the medullary cavity of trabecular bone was sparse, the number of trabecular bones was decreased, trabecular separation was increased, bone marrow </span>mineralization was enhanced, osteoclastic activity was increased, and circulating GH-IGF1-IGFBP3 levels were decreased. However, RT-PCR reaction results of localized </span>proximal tibiae showed upregulation of IGF1 and downregulation of IGFBP3.</span></p></div><div><h3>Conclusions</h3><p>High-dose ATRA intake over a short period of time can reduce GH-IGF1-IGFBP3 levels, affect cartilage and bone homeostasis, and inhibit bone growth in developing animals.</p></div>","PeriodicalId":12803,"journal":{"name":"Growth Hormone & Igf Research","volume":"62 ","pages":"Article 101446"},"PeriodicalIF":1.4,"publicationDate":"2022-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39911457","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-02-01DOI: 10.1016/j.ghir.2022.101444
Rafaela S. Girão , Manuel H. Aguiar-Oliveira , Bruna M.R. Andrade , Marcos A.V. Bittencourt , Roberto Salvatori , Evânio V. Silva , André L.M. Santos , Matheus M. Cunha , Wilton M. Takeshita , Alaíde H.A. Oliveira , Eugênia H.O. Valença , Alécia A. Oliveira-Santos , Luiz A. Oliveira-Neto
Objectives
The growth of the dental arches depends on GH and insulin-like growth factor type 1 (IGF1), but the consequences of GH deficiency (GHD) on their growth are still unclear, probably due to the acquired etiology of GHD in most described series, often associated with additional pituitary deficits (thyrotrophic, corticotrophic and gonadotrophic hormones), and imperfections of related replacement therapies, which may affect the dental arch growth. To avoid these limitations, we took advantage of a unique cohort of subjects with isolated GH deficiency (IGHD) due the same mutation in the GH releasing hormone receptor gene, living with very low serum GH and low to undetectable circulating IGF1 levels. Our purpose was to analyze the dimensions of maxillary and mandibular dental arches.
Methods
22 adult IGHD (15 untreated and 7 previously partially treated with GH) and 33 controls were enrolled in a cross-sectional study using the Ortho Insight 3D and MeshMixer software,
Results
In untreated IGHD subjects all maxillary arch measures were smaller than controls, while among mandibular arches, only the mandibular canine width and the mandibular arch length were reduced. In partially GH treated subjects only the palate depth, the maxillary canine width, the maxillary and mandibular arch lengths remained smaller than controls.
Conclusions
IGHD reduces the growth of maxillary arch to a greater degree than the mandibular arch, suggesting different control of superior and inferior dental arches. GH treatment increases some of these measures.
{"title":"Dental arches in inherited severe isolated growth hormone deficiency","authors":"Rafaela S. Girão , Manuel H. Aguiar-Oliveira , Bruna M.R. Andrade , Marcos A.V. Bittencourt , Roberto Salvatori , Evânio V. Silva , André L.M. Santos , Matheus M. Cunha , Wilton M. Takeshita , Alaíde H.A. Oliveira , Eugênia H.O. Valença , Alécia A. Oliveira-Santos , Luiz A. Oliveira-Neto","doi":"10.1016/j.ghir.2022.101444","DOIUrl":"10.1016/j.ghir.2022.101444","url":null,"abstract":"<div><h3>Objectives</h3><p><span>The growth of the dental arches depends on GH and insulin-like growth factor type 1 (IGF1), but the consequences of GH deficiency (GHD) on their growth are still unclear, probably due to the acquired etiology of GHD in most described series, often associated with additional pituitary deficits (thyrotrophic, corticotrophic and gonadotrophic hormones), and imperfections of related replacement therapies, which may affect the dental arch growth. To avoid these limitations, we took advantage of a unique cohort of subjects with isolated GH deficiency (IGHD) due the same mutation in the </span>GH releasing hormone<span> receptor gene<span>, living with very low serum GH and low to undetectable circulating IGF1 levels. Our purpose was to analyze the dimensions of maxillary and mandibular dental arches.</span></span></p></div><div><h3>Methods</h3><p>22 adult IGHD (15 untreated and 7 previously partially treated with GH) and 33 controls were enrolled in a cross-sectional study using the Ortho Insight 3D and MeshMixer software,</p></div><div><h3>Results</h3><p>In untreated IGHD subjects all maxillary arch measures were smaller than controls, while among mandibular arches, only the mandibular canine<span><span> width and the mandibular arch length were reduced. In partially GH treated subjects only the palate depth, the </span>maxillary canine width, the maxillary and mandibular arch lengths remained smaller than controls.</span></p></div><div><h3>Conclusions</h3><p>IGHD reduces the growth of maxillary arch to a greater degree than the mandibular arch, suggesting different control of superior and inferior dental arches. GH treatment increases some of these measures.</p></div>","PeriodicalId":12803,"journal":{"name":"Growth Hormone & Igf Research","volume":"62 ","pages":"Article 101444"},"PeriodicalIF":1.4,"publicationDate":"2022-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39912507","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-02-01DOI: 10.1016/j.ghir.2021.101440
Stuart A. Morgan , Darlene E. Berryman , Edward O. List , Gareth G. Lavery , Paul M. Stewart , John J. Kopchick
Patients with growth hormone deficiency (GHD) have many clinical features in common with Cushing's syndrome (glucocorticoid excess) – notably visceral obesity, insulin resistance, muscle myopathy and increased vascular mortality. Within key metabolic tissues, 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) converts cortisone to the active glucocorticoid, cortisol (11-dehydrocorticosterone and corticosterone in rodents respectively), and thus amplifies local glucocorticoid action.
We hypothesize that 11β-HSD1 expression is negatively regulated by growth hormone (GH), and that GHD patients have elevated 11β-HSD1 within key metabolic tissues (leading to increased intracellular cortisol generation) which contributes to the clinical features of this disease.
To identify the impact of GH excess/resistance on 11β-HSD1 in vivo, we measured mRNA expression in key metabolic tissues of giant mice expressing the bovine GH (bGH) gene, dwarf mice with a disrupted GH receptor (GHRKO) gene and mice expressing a gene encoding a GH receptor antagonist (GHA). Additionally, we assessed urine steroid markers of 11β-HSD1 activity in both GHRKO and bGH animals.
11β-HSD1 expression was decreased in gastrocnemius muscle (0.43-fold, p < 0.05), subcutaneous adipose (0.53-fold, p < 0.05) and epididymal adipose tissue (0.40-fold, p < 0.05), but not liver, in bGH mice compared to WT controls. This was paralleled by an increased percentage of 11-DHC (inactive glucocorticoid) present in the urine of bGH mice compared to WT controls (2.5-fold, p < 0.01) - consistent with decreased systemic 11β-HSD1 activity. By contrast, expression of 11β-HSD1 was increased in the liver of GHRKO (2.7-fold, p < 0.05) and GHA mice (2.0-fold, p < 0.05) compared to WT controls, but not gastrocnemius muscle, subcutaneous adipose tissue or epididymal adipose tissue.
In summary, we have demonstrated a negative relationship between GH action and 11β-HSD1 expression which appears to be tissue specific. These data provide evidence that increased intracellular cortisol production within key tissues may contribute to metabolic disease in GHD patients.
{"title":"Regulation of 11β-HSD1 by GH/IGF-1 in key metabolic tissues may contribute to metabolic disease in GH deficient patients","authors":"Stuart A. Morgan , Darlene E. Berryman , Edward O. List , Gareth G. Lavery , Paul M. Stewart , John J. Kopchick","doi":"10.1016/j.ghir.2021.101440","DOIUrl":"10.1016/j.ghir.2021.101440","url":null,"abstract":"<div><p><span><span>Patients with growth hormone deficiency<span> (GHD) have many clinical features in common with Cushing's syndrome (glucocorticoid excess) – notably visceral obesity, insulin resistance, muscle </span></span>myopathy<span><span> and increased vascular mortality. Within key metabolic tissues, 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) converts cortisone to the active </span>glucocorticoid<span>, cortisol (11-dehydrocorticosterone and </span></span></span>corticosterone in rodents respectively), and thus amplifies local glucocorticoid action.</p><p>We hypothesize that 11β-HSD1 expression is negatively regulated by growth hormone (GH), and that GHD patients have elevated 11β-HSD1 within key metabolic tissues (leading to increased intracellular cortisol generation) which contributes to the clinical features of this disease.</p><p>To identify the impact of GH excess/resistance on 11β-HSD1 <em>in vivo</em><span><span><span>, we measured mRNA expression in key metabolic tissues of giant mice expressing the bovine GH (bGH) gene, dwarf mice with a disrupted </span>GH receptor (GHRKO) gene and mice expressing a gene encoding a GH </span>receptor antagonist<span> (GHA). Additionally, we assessed urine steroid markers of 11β-HSD1 activity in both GHRKO and bGH animals.</span></span></p><p><span>11β-HSD1 expression was decreased in gastrocnemius muscle (0.43-fold, </span><em>p</em><span> < 0.05), subcutaneous adipose (0.53-fold, </span><em>p</em> < 0.05) and epididymal adipose tissue (0.40-fold, <em>p</em> < 0.05), but not liver, in bGH mice compared to WT controls. This was paralleled by an increased percentage of 11-DHC (inactive glucocorticoid) present in the urine of bGH mice compared to WT controls (2.5-fold, <em>p</em> < 0.01) - consistent with decreased systemic 11β-HSD1 activity. By contrast, expression of 11β-HSD1 was increased in the liver of GHRKO (2.7-fold, <em>p</em> < 0.05) and GHA mice (2.0-fold, <em>p</em> < 0.05) compared to WT controls, but not gastrocnemius muscle, subcutaneous adipose tissue or epididymal adipose tissue.</p><p>In summary, we have demonstrated a negative relationship between GH action and 11β-HSD1 expression which appears to be tissue specific. These data provide evidence that increased intracellular cortisol production within key tissues may contribute to metabolic disease in GHD patients.</p></div>","PeriodicalId":12803,"journal":{"name":"Growth Hormone & Igf Research","volume":"62 ","pages":"Article 101440"},"PeriodicalIF":1.4,"publicationDate":"2022-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39651866","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
To identify and characterize a novel deletion at the LHX4 gene locus in a proband with growth hormone deficiency (GHD).
Methods
Long range polymerase chain reaction (PCR) amplification was used to confirm the suspected deletion and to identify the rough locations of the end points. Sanger sequencing was carried out to identify the exact end points of the deletion.
Results
Suspected deletion was confirmed via long range PCR amplification. Sanger sequencing identified the end points of the deletion within three nucleotide repeat sequences (“CTT”). The total length of the deleted segment was 12 127 base pairs and it includes complete exon 5 and exon 6 of the LHX4 gene. Therefore the homeodomain motif coded by exons 4 and 5, might be affected.
Conclusion
We have identified a novel deletion that spans exon 5 and exon 6 of the LHX4 gene that could have occurred via microhomology mediated non-recurrent rearrangement. The deletion characterized does not appear to have been reported before. To our knowledge this novel deletion is the first identified LHX4 variant from Sri Lanka and it explains the phenotype of the proband characterized by growth hormone deficiency, hypoplastic anterior pituitary and subsequent deficiency of thyroid stimulating hormone and adrenocorticotropic hormone (ACTH).
{"title":"Novel gross deletion at the LHX4 gene locus in a child with growth hormone deficiency","authors":"Saumya Madushani Samarasinghe , Tharmini Sundralingam , Asanka Sudeshini Hewage , K.S.H. de Silva , Kamani Hemamala Tennekoon","doi":"10.1016/j.ghir.2021.101443","DOIUrl":"10.1016/j.ghir.2021.101443","url":null,"abstract":"<div><h3>Objective</h3><p>To identify and characterize a novel deletion at the <span><em>LHX4</em></span><span> gene locus<span><span> in a proband with </span>growth hormone deficiency (GHD).</span></span></p></div><div><h3>Methods</h3><p>Long range polymerase chain reaction<span> (PCR) amplification was used to confirm the suspected deletion and to identify the rough locations of the end points. Sanger sequencing was carried out to identify the exact end points of the deletion.</span></p></div><div><h3>Results</h3><p><span>Suspected deletion was confirmed via long range PCR amplification. Sanger sequencing identified the end points of the deletion within three nucleotide repeat sequences (“CTT”). The total length of the deleted segment was 12 127 base pairs and it includes complete exon 5 and exon 6 of the </span><em>LHX4</em><span> gene. Therefore the homeodomain motif coded by exons 4 and 5, might be affected</span><del>.</del></p></div><div><h3>Conclusion</h3><p>We have identified a novel deletion that spans exon 5 and exon 6 of the <em>LHX4</em> gene that could have occurred via microhomology mediated non-recurrent rearrangement. The deletion characterized does not appear to have been reported before. To our knowledge this novel deletion is the first identified <em>LHX4</em><span><span> variant from Sri Lanka and it explains the phenotype of the proband characterized by growth hormone deficiency, hypoplastic anterior pituitary and subsequent deficiency of thyroid stimulating hormone and </span>adrenocorticotropic hormone (ACTH).</span></p></div>","PeriodicalId":12803,"journal":{"name":"Growth Hormone & Igf Research","volume":"62 ","pages":"Article 101443"},"PeriodicalIF":1.4,"publicationDate":"2022-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39888615","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pituitary diseases may cause psychiatric and personality alterations. We aimed to compare the personality traits of acromegalic patients with those of patients with non-functioning pituitary adenomas and a healthy control group.
Design
Fifty-eight acromegalic patients, 45 patients with non-functioning adenoma, and 40 healthy subjects were enrolled in the study. Cloninger's Temperament and Character Inventory (TCI), Beck Depression Inventory, Beck Anxiety Inventory, and Rosenberg Self-Esteem Scale (RSES) were used to assess personality, depression, anxiety, and self-esteem.
Results
Depression score was higher in acromegaly and non-functioning adenoma groups than healthy controls. RSES scores were similar among the three groups. Regarding the scales of TCI, only novelty-seeking was significantly reduced in acromegaly and non-functioning adenoma than the control group. Pairwise comparisons revealed that the difference was due to the difference between acromegalic patients and controls. Scales of TCI were correlated with depression and anxiety in patients with acromegaly and non-functioning adenoma but not in healthy controls.
Conclusion
This study showed that novelty-seeking was reduced in patients with acromegaly. Both the hormonal lack and excess and structural changes can lead to cognitive and personality changes in acromegaly. More studies are needed to be carried out about personality characteristics in pituitary diseases.
{"title":"Personality traits in acromegalic patients: Comparison with patients with non-functioning adenomas and healthy controls","authors":"Elif Kilic Kan , Aysegul Atmaca , Gokhan Sarisoy , Gulcin Cengiz Ecemis , Feyzi Gokosmanoglu","doi":"10.1016/j.ghir.2021.101439","DOIUrl":"10.1016/j.ghir.2021.101439","url":null,"abstract":"<div><h3>Objectives</h3><p>Pituitary diseases may cause psychiatric and personality alterations. We aimed to compare the personality traits of acromegalic patients with those of patients with non-functioning pituitary adenomas and a healthy control group.</p></div><div><h3>Design</h3><p><span>Fifty-eight acromegalic patients, 45 patients with non-functioning adenoma<span>, and 40 healthy subjects were enrolled in the study. Cloninger's Temperament and Character Inventory (TCI), Beck Depression Inventory, </span></span>Beck Anxiety Inventory, and Rosenberg Self-Esteem Scale (RSES) were used to assess personality, depression, anxiety, and self-esteem.</p></div><div><h3>Results</h3><p><span>Depression score was higher in acromegaly and non-functioning adenoma groups than healthy controls. RSES scores were similar among the three groups. Regarding the scales of TCI, only novelty-seeking was significantly reduced in acromegaly and non-functioning adenoma than the control group. Pairwise comparisons revealed that the difference was due to the difference between acromegalic patients and controls. Scales of TCI were correlated with depression and anxiety </span>in patients with acromegaly and non-functioning adenoma but not in healthy controls.</p></div><div><h3>Conclusion</h3><p>This study showed that novelty-seeking was reduced in patients with acromegaly. Both the hormonal lack and excess and structural changes can lead to cognitive and personality changes in acromegaly. More studies are needed to be carried out about personality characteristics in pituitary diseases.</p></div>","PeriodicalId":12803,"journal":{"name":"Growth Hormone & Igf Research","volume":"62 ","pages":"Article 101439"},"PeriodicalIF":1.4,"publicationDate":"2022-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39651867","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}